SCHEMBL2899501

SCHEMBL2899501

COC(=O)C(CF)(Cc1cccc(OS(=O)(=O)C(F)(F)F)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRB P23467 4/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CTSK P43235 2/20 0.34
DRD2 P14416 2/20 0.33
DRD1 P21728 2/20 0.33
DRD4 P21917 2/20 0.33
DRD5 P21918 2/20 0.33
DRD3 P35462 2/20 0.33
KLK5 Q9Y337 1/20 0.33
CACNA1B Q00975 1/20 0.33
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
ACP1 P24666 1/20 0.33
CTSS P25774 1/20 0.33
CTSD P07339 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12621537 0.88 PTPRB (0.41) PTPRBCA12CA1CA7CA14
SCHEMBL2896129 0.82 NQO2 (0.38) PTPRBCA12CA1CA7CA14
SCHEMBL12621540 0.81 CA12 (0.40) PTPRBCA12CA1CA7CA14
SCHEMBL20103512 0.79 PTPRB (0.46) PTPRBMEN1KMT2ADRD2DRD1
SCHEMBL16168349 0.77 CA12 (0.47) CA12CA1CA7CA14
SCHEMBL22033107 0.76 MEN1 (0.43) PTPRBMEN1KMT2ACTSKCACNA1B
SCHEMBL30460512 0.76 MEN1 (0.43) PTPRBMEN1KMT2ACTSKCACNA1B
SCHEMBL781652 0.76 NQO2 (0.47) CA12CA1CA7CA14MEN1
SCHEMBL12621543 0.74 PTPRB (0.46) PTPRBCA12CA1CA7CA14
SCHEMBL29454657 0.74 PPARG (0.44) PTPRBDRD2DRD1DRD4DRD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814537-B1 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK SHARP & DOHME (US) 2014-11-12 EP disclosed
US-7678783-B2 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2010-03-16 US disclosed
US-7678783-B2 Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease MERCK SHARP & DOHME CORP. (US) 2010-03-16 US disclosed
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2008-10-30 US disclosed
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2008-10-30 US disclosed
EP-1814537-A2 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2007-08-08 EP disclosed
WO-2006055434-A2 MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2006-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269302-A1 Macrocyclic Tertiary Amine Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 PTPRB 4028/4885CA12 3598/4885CA1 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.